These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7362649)

  • 1. Importance of the lactonic ring in the activity of steroidal antialdosterones.
    Peterfalvi M; Torelli V; Fournex R; Rousseau G; Claire M; Michaud A; Corvol P
    Biochem Pharmacol; 1980 Feb; 29(3):353-7. PubMed ID: 7362649
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of the antimineralocorticoid effects of spirolactones.
    Corvol P; Claire M; Oblin ME; Geering K; Rossier B
    Kidney Int; 1981 Jul; 20(1):1-6. PubMed ID: 7029118
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of spironolactones on aldosterone synthesis and adrenal metabolism].
    Aupetit B; Duchier J; Legrand JC
    Ann Endocrinol (Paris); 1978; 39(5):355-72. PubMed ID: 742835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.
    Dasgupta A; Saffer H; Wells A; Datta P
    J Clin Lab Anal; 2002; 16(4):172-7. PubMed ID: 12112389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
    Dasgupta A; Johnson MJ
    J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.
    Levine D; Ramsay L; Auty R; Branch R; Tidd M
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):381-6. PubMed ID: 786663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative potency of prorenoate and spironolactone in normal man.
    Ramsay L; Harrison I; Shelton J; Tidd M
    Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and comparative evaluation of aldosterone antagonists in glucocorticoid-treated, adrenalectomized rats.
    Casals-Stenzel J; Buse M; Losert W
    Eur J Pharmacol; 1982 May; 80(1):37-45. PubMed ID: 7095004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
    Cheng SC; Suzuki K; Sadee W; Harding BW
    Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors.
    Funder JW; Feldman D; Highland E; Edelman IS
    Biochem Pharmacol; 1974 May; 23(10):1493-501. PubMed ID: 4367952
    [No Abstract]   [Full Text] [Related]  

  • 13. Aldosterone antagonists. 4. Synthesis and activities of steroidal 6,6-ethylene-15,16-methylene 17-spirolactones.
    Nickisch K; Beier S; Bittler D; Elger W; Laurent H; Losert W; Nishino Y; Schillinger E; Wiechert R
    J Med Chem; 1991 Aug; 34(8):2464-8. PubMed ID: 1875342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3- (16Beta,17beta-dihydroxy-3-oxoandrost-4-en-17alpha-yl) propionic acid gamma-lactone, its preparation and antimineralocorticoid activity.
    Chinn LJ; Hofmann LM
    J Med Chem; 1973 Jul; 16(7):839-43. PubMed ID: 4725930
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of spironolactone on transport of Na+, K+ and H+. A microperfusion study in rat main submaxillary duct.
    Knauf H
    Eur J Clin Invest; 1976 Jan; 6(1):17-20. PubMed ID: 1253806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical potassium excretion in response to aldosterone antagonists.
    Ramsay LE; Harrison IR; Shelton JR; Tidd MJ
    Eur J Clin Pharmacol; 1977 Jan; 11(2):101-5. PubMed ID: 837961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-angiogenic effects of aldosterone antagonists in the fibrin chamber in rats].
    Guggino S; Mechine Neuville A; Weltin D; Imbs JL; Stephan D
    Arch Mal Coeur Vaiss; 2003; 96(7-8):808-10. PubMed ID: 12945230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.
    Armanini D; Sabbadin C; Donà G; Clari G; Bordin L
    Expert Opin Pharmacother; 2014 May; 15(7):909-12. PubMed ID: 24617854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.